Aelis Farma, of Bordeaux, France, said it completed an €11 million (US$12.2 million) financing round with the Region Nouvelle Aquitaine, Inserm Transfert Initiative, Bpifrance and the ACI, NACO and Aelis Innovation (a fund of IRDI Soridec Gestion) regional funds participating. This round, combined with €9 million in research grants, will allow the completion of phase II trials for the treatment of cannabis-related disorders. The first study, in collaboration with Columbia University, is analyzing AEF-0117’s effects on 64 patients with cannabis addiction; the second study will assess the effects of AEF-0117 on the psychotic symptomatology induced by cannabis. The company is developing the signaling specific inhibitors of the CB-1 receptor, a new class of drugs implicated in numerous disorders of the nervous system.
Assembly Biosciences Inc., of South San Francisco, said it priced an underwritten public offering of 5.15 million shares at $16.50 each. In addition, and in lieu of common stock, it is offering to a certain existing investor pre-funded warrants to purchase up to an aggregate of 2.42 million shares at $16.499 per pre-funded warrant. The gross proceeds are expected to be approximately $125 million. The underwriters have been granted a 30-day option to purchase up to an additional 1.136 million shares. The company intends to use the net proceeds from the sale of the common stock to fund clinical trials, nonclinical studies, research and development and for general corporate purposes.
Omeros Corp., of Seattle, said the underwriter of its public offering exercised in full its option to purchase 572,518 shares. This brings the total shares sold 4.389 million at $13.10 each for gross proceeds of approximately $57.5 million. The company intends to use the net proceeds for general corporate purposes, including funding clinical trials, pre-clinical studies, manufacturing, build out of commercial infrastructure and other costs associated with advancing its development programs and product candidates toward regulatory submissions and potential commercialization.
Sarepta Therapeutics Inc., of Cambridge, Mass., said it entered into an agreement with funds managed by Pharmakon Advisors LP, that provides up to $500 million of borrowing capacity in two tranches. The first $250 million (tranche A) will be available shortly after closing, with an additional $250 million (tranche B) available at Sarepta’s option by December 31, 2020, subject to certain conditions. Both tranches are available at an interest rate of 8.5% annually, payable quarterly. The facility will mature 48 months from the tranche A closing date.